# Blaize Holdings, Inc.: financial statements, quarterly

BZAI · Nasdaq · CIK 1871638 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bzai.md) · [Financials](/companies/bzai/financials.md) · [Filings](/companies/bzai/filings.md) · [Insiders](/companies/bzai/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bzai/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.5](/filings/0000950170-25-071593.md) | [0.2](/filings/0000950170-25-108998.md) | [0.8](/filings/0001193125-25-280252.md) | [0.0 d](/filings/0001871638-26-000011.md) | [1.0](/filings/0001871638-26-000035.md) | [2.0](/filings/0001871638-26-000046.md) | [11.9](/filings/0001193125-25-280252.md) | [23.8 d](/filings/0001871638-26-000011.md) | [2.7](/filings/0001871638-26-000035.md) | [12.0](/filings/0001871638-26-000046.md) |
| Cost of revenue | $m | not reported | not reported | [0.3](/filings/0000950170-25-071593.md) | [0.3](/filings/0000950170-25-108998.md) | [0.5](/filings/0001193125-25-280252.md) | [(0.5) d](/filings/0001871638-26-000011.md) | [0.3](/filings/0001871638-26-000035.md) | [0.8](/filings/0001871638-26-000046.md) | [10.1](/filings/0001193125-25-280252.md) | [21.2 d](/filings/0001871638-26-000011.md) | [1.2](/filings/0001871638-26-000035.md) | [11.1](/filings/0001871638-26-000046.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | [0.3](/filings/0001193125-25-280252.md) | [0.5 d](/filings/0001871638-26-000011.md) | [0.7](/filings/0001871638-26-000035.md) | [1.2](/filings/0001871638-26-000046.md) | [1.8](/filings/0001193125-25-280252.md) | [2.6 d](/filings/0001871638-26-000011.md) | [1.6](/filings/0001871638-26-000035.md) | [0.9](/filings/0001871638-26-000046.md) |
| Research and development | $m | not reported | not reported | [4.1](/filings/0000950170-25-071593.md) | [5.9](/filings/0000950170-25-108998.md) | [5.8](/filings/0001193125-25-280252.md) | [9.3 d](/filings/0001871638-26-000011.md) | [13.1](/filings/0001871638-26-000035.md) | [9.6](/filings/0001871638-26-000046.md) | [9.7](/filings/0001193125-25-280252.md) | [10.1 d](/filings/0001871638-26-000011.md) | [9.7](/filings/0001871638-26-000035.md) | [10.5](/filings/0001871638-26-000046.md) |
| Selling, general and administrative | $m | not reported | not reported | [4.0](/filings/0000950170-25-071593.md) | [5.0](/filings/0000950170-25-108998.md) | [5.5](/filings/0001193125-25-280252.md) | not reported | [13.4](/filings/0000950170-25-071593.md) | [13.0](/filings/0000950170-25-108998.md) | [14.3](/filings/0001193125-25-280252.md) | not reported | not reported | not reported |
| Operating income | $m | [(0.7)](/filings/0001410578-24-001835.md) | [(1.2) d](/filings/0000950170-25-053870.md) | [(8.1)](/filings/0000950170-25-071593.md) | [(11.1)](/filings/0000950170-25-108998.md) | [(11.4)](/filings/0001193125-25-280252.md) | [(17.0) d](/filings/0001871638-26-000011.md) | [(38.0)](/filings/0001871638-26-000035.md) | [(21.9)](/filings/0001871638-26-000046.md) | [(22.6)](/filings/0001193125-25-280252.md) | [(21.4) d](/filings/0001871638-26-000011.md) | [(23.4)](/filings/0001871638-26-000035.md) | [(30.6)](/filings/0001871638-26-000046.md) |
| Income tax | $m | [0.2](/filings/0001410578-24-001835.md) | [0.1 d](/filings/0000950170-25-053870.md) | [0.2](/filings/0000950170-25-071593.md) | [0.1](/filings/0000950170-25-108998.md) | [0.1](/filings/0001193125-25-280252.md) | [(1.3) d](/filings/0001871638-26-000011.md) | [0.2](/filings/0001871638-26-000035.md) | [0.0](/filings/0001871638-26-000046.md) | [0.0](/filings/0001193125-25-280252.md) | [(0.0) d](/filings/0001871638-26-000011.md) | [0.1](/filings/0001871638-26-000035.md) | [0.3](/filings/0001871638-26-000046.md) |
| Net income | $m | [0.0](/filings/0001410578-24-001835.md) | [(0.3) d](/filings/0000950170-25-053870.md) | [(16.7)](/filings/0000950170-25-071593.md) | [(12.2)](/filings/0000950170-25-108998.md) | [(25.6)](/filings/0001193125-25-280252.md) | [(6.7) d](/filings/0001871638-26-000011.md) | [(148)](/filings/0001871638-26-000035.md) | [(29.6)](/filings/0001871638-26-000046.md) | [(26.3)](/filings/0001193125-25-280252.md) | [(3.3) d](/filings/0001871638-26-000011.md) | [(22.7)](/filings/0001871638-26-000035.md) | [(28.8)](/filings/0001871638-26-000046.md) |
| Diluted EPS | $ per share | not reported | not reported | [(1.23)](/filings/0000950170-25-071593.md) | [(0.89)](/filings/0000950170-25-108998.md) | [(1.47)](/filings/0001193125-25-280252.md) | not reported | [(1.61)](/filings/0001871638-26-000035.md) | [(0.28)](/filings/0001871638-26-000046.md) | [(0.25)](/filings/0001193125-25-280252.md) | not reported | [(0.19)](/filings/0001871638-26-000035.md) | [(0.21)](/filings/0001871638-26-000046.md) |
| Basic EPS | $ per share | not reported | not reported | [(1.23)](/filings/0000950170-25-071593.md) | [(0.89)](/filings/0000950170-25-108998.md) | [(1.47)](/filings/0001193125-25-280252.md) | not reported | [(1.61)](/filings/0001871638-26-000035.md) | [(0.28)](/filings/0001871638-26-000046.md) | [(0.25)](/filings/0001193125-25-280252.md) | not reported | [(0.19)](/filings/0001871638-26-000035.md) | [(0.21)](/filings/0001871638-26-000046.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.0](/filings/0001410578-24-001835.md) | [0.0](/filings/0000950170-25-053870.md) | [7.0](/filings/0000950170-25-071593.md) | [87.4](/filings/0000950170-25-108998.md) | [68.6](/filings/0001193125-25-280252.md) | [50.2](/filings/0001871638-26-000011.md) | [45.0](/filings/0001871638-26-000035.md) | [28.6](/filings/0001871638-26-000046.md) | [24.0](/filings/0001193125-25-280252.md) | [45.8](/filings/0001871638-26-000046.md) | [33.2](/filings/0001871638-26-000035.md) | [36.8](/filings/0001871638-26-000046.md) |
| Current assets | $m | [0.1](/filings/0001410578-23-002437.md) | [25.7](/filings/0000950170-25-053870.md) | [0.3](/filings/0001410578-24-000994.md) | [0.2](/filings/0001410578-24-001376.md) | [0.2](/filings/0001410578-24-001835.md) | [71.7](/filings/0001871638-26-000011.md) | [93.5](/filings/0000950170-25-071593.md) | [47.4](/filings/0000950170-25-108998.md) | [54.8](/filings/0001193125-25-280252.md) | [96.6](/filings/0001871638-26-000046.md) | [65.4](/filings/0001871638-26-000035.md) | [74.0](/filings/0001871638-26-000046.md) |
| Total assets | $m | [70.9](/filings/0001410578-23-002437.md) | [72.6](/filings/0000950170-25-053870.md) | [48.1](/filings/0001410578-24-000994.md) | [49.1](/filings/0001410578-24-001376.md) | [50.1](/filings/0001410578-24-001835.md) | [78.5](/filings/0001871638-26-000011.md) | [100](/filings/0000950170-25-071593.md) | [53.8](/filings/0000950170-25-108998.md) | [60.9](/filings/0001193125-25-280252.md) | [102](/filings/0001871638-26-000046.md) | [70.8](/filings/0001871638-26-000035.md) | [79.5](/filings/0001871638-26-000046.md) |
| Current liabilities | $m | [4.5](/filings/0001410578-23-002437.md) | [31.4](/filings/0000950170-25-053870.md) | [6.9](/filings/0001410578-24-000994.md) | [8.5](/filings/0001410578-24-001376.md) | [10.4](/filings/0001410578-24-001835.md) | [186](/filings/0001871638-26-000011.md) | [38.4](/filings/0000950170-25-071593.md) | [39.6](/filings/0000950170-25-108998.md) | [36.8](/filings/0001193125-25-280252.md) | [43.4](/filings/0001871638-26-000046.md) | [26.5](/filings/0001871638-26-000035.md) | [19.9](/filings/0001871638-26-000046.md) |
| Total liabilities | $m | [14.6](/filings/0001410578-23-002437.md) | [41.4](/filings/0000950170-25-053870.md) | [17.0](/filings/0001410578-24-000994.md) | [18.5](/filings/0001410578-24-001376.md) | [20.4](/filings/0001410578-24-001835.md) | [189](/filings/0001871638-26-000011.md) | [50.4](/filings/0000950170-25-071593.md) | [58.6](/filings/0000950170-25-108998.md) | [59.6](/filings/0001193125-25-280252.md) | [63.2](/filings/0001871638-26-000046.md) | [45.3](/filings/0001871638-26-000035.md) | [36.7](/filings/0001871638-26-000046.md) |
| Shareholders' equity | $m | [(14.3)](/filings/0001410578-24-001835.md) | [(53.2)](/filings/0001871638-26-000011.md) | [(69.6)](/filings/0000950170-25-108998.md) | [(81.4)](/filings/0001193125-25-280252.md) | [(107)](/filings/0001193125-25-280252.md) | [(110)](/filings/0001871638-26-000046.md) | [16.7](/filings/0001871638-26-000046.md) | [(4.8)](/filings/0001871638-26-000046.md) | [1.3](/filings/0001193125-25-280252.md) | [39.0](/filings/0001871638-26-000046.md) | [25.4](/filings/0001871638-26-000046.md) | [42.8](/filings/0001871638-26-000046.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.3) d](/filings/0001410578-24-001835.md) | [(0.2) d](/filings/0000950170-25-053870.md) | [(7.4)](/filings/0000950170-25-071593.md) | [(14.3) d](/filings/0000950170-25-108998.md) | [(14.2) d](/filings/0001193125-25-280252.md) | [(17.7) d](/filings/0001871638-26-000011.md) | [(15.9)](/filings/0001871638-26-000035.md) | [(16.4) d](/filings/0001871638-26-000046.md) | [(24.9) d](/filings/0001193125-25-280252.md) | [(16.5) d](/filings/0001871638-26-000011.md) | [(12.6)](/filings/0001871638-26-000035.md) | [(28.7) d](/filings/0001871638-26-000046.md) |
| Capital expenditure | $m | not reported | not reported | [0.2](/filings/0000950170-25-071593.md) | [(0.1) d](/filings/0000950170-25-108998.md) | [1.1 d](/filings/0001193125-25-280252.md) | [(0.3) d](/filings/0001871638-26-000011.md) | [0.7](/filings/0001871638-26-000035.md) | [0.0 d](/filings/0001871638-26-000046.md) | [0.0 d](/filings/0001193125-25-280252.md) | [0.1 d](/filings/0001871638-26-000011.md) | [0.1](/filings/0001871638-26-000035.md) | [0.5 d](/filings/0001871638-26-000046.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.6](/filings/0000950170-25-071593.md) | [13.6](/filings/0000950170-25-108998.md) | [17.5](/filings/0001193125-25-280252.md) | [91.7](/filings/0001871638-26-000035.md) | [105](/filings/0001871638-26-000046.md) | [104](/filings/0001193125-25-280252.md) | [122](/filings/0001871638-26-000035.md) | [135](/filings/0001871638-26-000046.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 144,832,039 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001871638-26-000046.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.